Lars Bo Nielsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lars Bo Nielsen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Christina Christoffersen
Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
8 shared publications Emil D. Bartels
Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
4 shared publicationsBjörn Dahlbäck
3 shared publications- Björn Dahlbäck
Department of Translational Medicine, Lund University, University Hospital, 21428 Malmö, Sweden
3 shared publications Emil Daniel Bartels
3 shared publicationsJens P. Goetze
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
3 shared publications
Latest Publications
- 1 April 2016
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (4) , 404-408
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis
- 1 April 2016
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (4) , 404-408
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis
- Open Access
- 25 February 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (3) , 4419-4431
The Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis
Apolipoprotein M (apoM) is a plasma apolipoprotein that mainly associates with high-density lipoproteins. Hence, most studies on apoM so far have investigated its effect on and association with lipid metabolism and atherosclerosis. The insight into apoM biology recently took a major turn. ApoM was identified as a carrier of the bioactive lipid sphingosine-1-phosphate (S1P). S1P activates five different G-protein-coupled receptors, known as the S1P-receptors 1–5 and, hence, affects a wide range of biological processes, such as lymphocyte trafficking, angiogenesis, wound repair and even virus suppression and cancer. The ability of apoM to bind S1P is due to a lipophilic binding pocket within the lipocalin structure of the apoM molecule. Mice overexpressing apoM have increased plasma S1P concentrations, whereas apoM-deficient mice have decreased S1P levels. ApoM-S1P is able to activate the S1P-receptor-1, affecting the function of endothelial cells, and apoM-deficient mice display impaired endothelial permeability in the lung. This review will focus on the putative biological roles of the new apoM–S1P axis in relation to lipoprotein metabolism, lipid disorders and atherosclerosis.
- 25 February 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (3) , 4419-4431
Open AccessThe Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis
Apolipoprotein M (apoM) is a plasma apolipoprotein that mainly associates with high-density lipoproteins. Hence, most studies on apoM so far have investigated its effect on and association with lipid metabolism and atherosclerosis. The insight into apoM biology recently took a major turn. ApoM was identified as a carrier of the bioactive lipid sphingosine-1-phosphate (S1P). S1P activates five different G-protein-coupled receptors, known as the S1P-receptors 1–5 and, hence, affects a wide range of biological processes, such as lymphocyte trafficking, angiogenesis, wound repair and even virus suppression and cancer. The ability of apoM to bind S1P is due to a lipophilic binding pocket within the lipocalin structure of the apoM molecule. Mice overexpressing apoM have increased plasma S1P concentrations, whereas apoM-deficient mice have decreased S1P levels. ApoM-S1P is able to activate the S1P-receptor-1, affecting the function of endothelial cells, and apoM-deficient mice display impaired endothelial permeability in the lung. This review will focus on the putative biological roles of the new apoM–S1P axis in relation to lipoprotein metabolism, lipid disorders and atherosclerosis.
- Open Access
- 1 October 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (10) , 2198-2204
The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles
- 1 October 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (10) , 2198-2204
Open AccessThe plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles
- Open Access
- 17 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , 126-2
Apolipoprotein M - a new biomarker in sepsis
Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.
- 17 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , 126-2
Open AccessApolipoprotein M - a new biomarker in sepsis
Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.
- Top Cited Papers
- 23 May 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (23) , 9613-9618
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Protection of the endothelium is provided by circulating sphingosine-1-phosphate (S1P), which maintains vascular integrity. We show that HDL-associated S1P is bound specifically to both human and murine apolipoprotein M (apoM). Thus, isolated human ApoM + HDL contained S1P, whereas ApoM − HDL did not. Moreover, HDL in Apom −/− mice contains no S1P, whereas HDL in transgenic mice overexpressing human apoM has an increased S1P content. The 1.7-Å structure of the S1P–human apoM complex reveals that S1P interacts specifically with an amphiphilic pocket in the lipocalin fold of apoM. Human ApoM + HDL induced S1P 1 receptor internalization, downstream MAPK and Akt activation, endothelial cell migration, and formation of endothelial adherens junctions, whereas apoM − HDL did not. Importantly, lack of S1P in the HDL fraction of Apom −/− mice decreased basal endothelial barrier function in lung tissue. Our results demonstrate that apoM, by delivering S1P to the S1P 1 receptor on endothelial cells, is a vasculoprotective constituent of HDL.
- 23 May 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (23) , 9613-9618
Top Cited PapersEndothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Protection of the endothelium is provided by circulating sphingosine-1-phosphate (S1P), which maintains vascular integrity. We show that HDL-associated S1P is bound specifically to both human and murine apolipoprotein M (apoM). Thus, isolated human ApoM + HDL contained S1P, whereas ApoM − HDL did not. Moreover, HDL in Apom −/− mice contains no S1P, whereas HDL in transgenic mice overexpressing human apoM has an increased S1P content. The 1.7-Å structure of the S1P–human apoM complex reveals that S1P interacts specifically with an amphiphilic pocket in the lipocalin fold of apoM. Human ApoM + HDL induced S1P 1 receptor internalization, downstream MAPK and Akt activation, endothelial cell migration, and formation of endothelial adherens junctions, whereas apoM − HDL did not. Importantly, lack of S1P in the HDL fraction of Apom −/− mice decreased basal endothelial barrier function in lung tissue. Our results demonstrate that apoM, by delivering S1P to the S1P 1 receptor on endothelial cells, is a vasculoprotective constituent of HDL.
- Open Access
- 1 October 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (10) , 2967-2975
Lipoprotein(a) accelerates atherosclerosis in uremic mice
- 1 October 2010
- Published by Elsevier in Journal of Lipid Research
- Vol. 51 (10) , 2967-2975
Open AccessLipoprotein(a) accelerates atherosclerosis in uremic mice
- 1 October 2010
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 31 (5) , 775
Decreased Expression of Natriuretic Peptides Associated with Lipid Accumulation in Cardiac Ventricle of Obese Mice
Plasma B-type natriuretic peptide (BNP) and proBNP are established markers of cardiac dysfunction. Even though obesity increases the risk of cardiovascular disease, obese individuals have reduced plasma concentrations of natriuretic peptides. The underlying mechanism is not established. We used cultured cardiomyocytes and three different mouse models to examine the impact of obesity and cardiac lipid accumulation on cardiac natriuretic peptide expression. The cardiac ventricular expression of atrial natriuretic peptide (ANP) and BNP mRNA and ANP peptide was decreased 36-72% in obese ob/ob, db/db, and fat-fed C57BL/6 mice as compared with their respective controls. The db/db and ob/ob mice displayed impaired cardiac function, whereas the fat-fed mice had almost normal cardiac function. Moreover, the ventricular expression of hypertrophic genes (α- and β-major histocompatibility complex and α-actin) and natriuretic peptide receptor genes were not consistently altered by obesity across the three mouse models. In contrast, cardiac ventricular triglycerides were similarly increased by 60-115% in all three obese mouse models and incubation with oleic acid caused triglyceride accumulation and an approximately 35% (P < 0.005) depression of ANP mRNA expression in cultured HL-1 atrial myocytes. The data suggest that obesity and altered cardiac lipid metabolism are associated with reduced production of ANP and BNP in the cardiac ventricles in the setting of normal as well as impaired cardiac function.
- 1 October 2010
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 31 (5) , 775
Decreased Expression of Natriuretic Peptides Associated with Lipid Accumulation in Cardiac Ventricle of Obese Mice
Plasma B-type natriuretic peptide (BNP) and proBNP are established markers of cardiac dysfunction. Even though obesity increases the risk of cardiovascular disease, obese individuals have reduced plasma concentrations of natriuretic peptides. The underlying mechanism is not established. We used cultured cardiomyocytes and three different mouse models to examine the impact of obesity and cardiac lipid accumulation on cardiac natriuretic peptide expression. The cardiac ventricular expression of atrial natriuretic peptide (ANP) and BNP mRNA and ANP peptide was decreased 36-72% in obese ob/ob, db/db, and fat-fed C57BL/6 mice as compared with their respective controls. The db/db and ob/ob mice displayed impaired cardiac function, whereas the fat-fed mice had almost normal cardiac function. Moreover, the ventricular expression of hypertrophic genes (α- and β-major histocompatibility complex and α-actin) and natriuretic peptide receptor genes were not consistently altered by obesity across the three mouse models. In contrast, cardiac ventricular triglycerides were similarly increased by 60-115% in all three obese mouse models and incubation with oleic acid caused triglyceride accumulation and an approximately 35% (P < 0.005) depression of ANP mRNA expression in cultured HL-1 atrial myocytes. The data suggest that obesity and altered cardiac lipid metabolism are associated with reduced production of ANP and BNP in the cardiac ventricles in the setting of normal as well as impaired cardiac function.
- 1 October 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (10) , 4779
Decreased Expression of Natriuretic Peptides Associated with Lipid Accumulation in Cardiac Ventricle of Obese Mice
- 1 October 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (10) , 4779
Decreased Expression of Natriuretic Peptides Associated with Lipid Accumulation in Cardiac Ventricle of Obese Mice
- Open Access
- 1 April 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (14) , 10583-10590
Expression of Apolipoprotein B in the Kidney Attenuates Renal Lipid Accumulation
- 1 April 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (14) , 10583-10590
Open AccessExpression of Apolipoprotein B in the Kidney Attenuates Renal Lipid Accumulation
- Open Access
- 11 August 2009
- Published by Wiley in Journal of Internal Medicine
- Vol. 266 (3) , 258-267
Apolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects
: Objective. Studies in mice suggest that plasma apoM is lowered in hyperinsulinaemic diabetes and that apoM stimulates formation of pre‐β‐HDL. Pre‐β‐HDL is an acceptor of cellular cholesterol and may be critical for reverse cholesterol transport. Herein, we examined whether patients with type 2 diabetes have reduced plasma apoM and whether apoM is associated with pre‐β‐HDL formation and cellular cholesterol efflux.Design. In 78 patients with type 2 diabetes and 89 control subjects, we measured plasma apoM with ELISA, pre‐β‐HDL and pre‐β‐HDL formation, phospholipid transfer protein (PLTP) activity and the ability of plasma to promote cholesterol efflux from cultured fibroblasts.Results. ApoM was ∼9% lower in patients with type 2 diabetes compared to controls (0.025 ± 0.006 vs. 0.027 ± 0.007 g L−1, P = 0.01). The difference in apoM was largely attributable to diabetes‐associated obesity. ApoM was positively related to both HDL (r = 0.16; P = 0.04) and LDL cholesterol (r = 0.28; P = 0.0003). Pre‐β‐HDL and pre‐β‐HDL formation were not different between diabetic and control subjects. ApoM predicted pre‐β‐HDL (r = 0.16; P = 0.04) and pre‐β‐HDL formation (r = 0.19; P = 0.02), even independently of positive relationships with apoA‐I, HDL‐cholesterol and PLTP activity. Cellular cholesterol efflux to plasma was positively related to pre‐β‐HDL and PLTP activity but not significantly to apoM.Conclusions. Plasma apoM is modestly reduced in type 2 diabetes. Pre‐β‐HDL and pre‐β‐HDL formation are positively associated with apoM, supporting the hypothesis that apoM plays a role in HDL remodelling in humans. Lower apoM may provide a mechanism to explain why pre‐β‐HDL formation is not increased in type 2 diabetes despite elevated PLTP activity.
- 11 August 2009
- Published by Wiley in Journal of Internal Medicine
- Vol. 266 (3) , 258-267
Open AccessApolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects
: Objective. Studies in mice suggest that plasma apoM is lowered in hyperinsulinaemic diabetes and that apoM stimulates formation of pre‐β‐HDL. Pre‐β‐HDL is an acceptor of cellular cholesterol and may be critical for reverse cholesterol transport. Herein, we examined whether patients with type 2 diabetes have reduced plasma apoM and whether apoM is associated with pre‐β‐HDL formation and cellular cholesterol efflux.Design. In 78 patients with type 2 diabetes and 89 control subjects, we measured plasma apoM with ELISA, pre‐β‐HDL and pre‐β‐HDL formation, phospholipid transfer protein (PLTP) activity and the ability of plasma to promote cholesterol efflux from cultured fibroblasts.Results. ApoM was ∼9% lower in patients with type 2 diabetes compared to controls (0.025 ± 0.006 vs. 0.027 ± 0.007 g L−1, P = 0.01). The difference in apoM was largely attributable to diabetes‐associated obesity. ApoM was positively related to both HDL (r = 0.16; P = 0.04) and LDL cholesterol (r = 0.28; P = 0.0003). Pre‐β‐HDL and pre‐β‐HDL formation were not different between diabetic and control subjects. ApoM predicted pre‐β‐HDL (r = 0.16; P = 0.04) and pre‐β‐HDL formation (r = 0.19; P = 0.02), even independently of positive relationships with apoA‐I, HDL‐cholesterol and PLTP activity. Cellular cholesterol efflux to plasma was positively related to pre‐β‐HDL and PLTP activity but not significantly to apoM.Conclusions. Plasma apoM is modestly reduced in type 2 diabetes. Pre‐β‐HDL and pre‐β‐HDL formation are positively associated with apoM, supporting the hypothesis that apoM plays a role in HDL remodelling in humans. Lower apoM may provide a mechanism to explain why pre‐β‐HDL formation is not increased in type 2 diabetes despite elevated PLTP activity.